retatrutide type 2 diabetes phase 2 results 2024 2025 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Efficacy and Safety of GLP‐1

Lp(a) was within range but the directional response to root-cause correction is the clinical signal worth noting

Despite media narratives that often frame GLP-1 drugs as empowering, over half of women (52%) and more than a third of men (37%) believe users are judged negatively, seen as taking the easy way out

Construction of inulin-based selenium nanoparticles to improve the antitumor activity of an inulin-type fructan from chicory

Around week 10 maybe

A study in the Journal of Pharmaceutical and Biomedical Analysis found that semaglutide exposed to room temperature (25C) loses 10-15% potency per month compared to refrigerated storage

The role of glucagon-like peptide-1 receptor agonists in chronic obstructive pulmonary disease